August 16, 2017

Alexion gets new U.S. patents for Soliris

New Haven-based Alexion Pharmaceuticals Inc. has received three new U.S. patents involving the composition and pharmaceutical formulations of its key rare blood-disorder drug, Soliris, and methods of treating an ultrarare autoimmune disorder with that drug.

The patents expire in 2027.

One new patent is directed to treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease, with Soliris, and it supplements other patents directed to treating atypical hemolytic uremic syndrome (aHUS) -- an ultrarare autoimmune disorder that can lead to dangerous blood-clotting.

Alexion is pursuing corresponding patent applications in other regions and countries, including Europe and Japan. It's also is pursuing patent applications for pending additional indications of Soliris, such as for the treatment of refractory generalized myasthenia gravis (gMG), a neuromuscular disease that can lead to attacks on muscle cell membranes, which can affect communication with nerve cells and loss of normal muscle function.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Is expanding the state-run CTtransit bus service from Hartford to Storrs smart policy?<>
Most Popular on Facebook
Copyright 2017 New England Business Media